Monitoring Growth and Health Over Time
At a Glance
DPM3-CDG requires lifelong, individualized monitoring because heart, breathing, neurologic, developmental, and emotional needs can change over time. Regular heart and breathing checks, seizure awareness, and coordinated support help the care team adjust care.
Monitoring DPM3-CDG is a lifelong process of “active observation.” Because the condition is ultra-rare, there is no single rulebook that applies to every person. Instead, your care team will extrapolate lessons learned from more common muscular dystrophies to create a personalized schedule [1][2].
Lifelong Heart Surveillance
The heart is a critical organ to monitor in DPM3-CDG. While muscle weakness in the arms and legs may progress slowly, heart issues like dilated cardiomyopathy can emerge silently [1].
- Routine Tests: Expect a baseline ECG (to check heart rhythm) and an echocardiogram (an ultrasound to check heart strength), followed by individualized repeat intervals determined by the cardiologist [1].
- Advanced Monitoring: If palpitations or fainting occur, the doctor may use a Holter monitor—a wearable device that records the heart’s rhythm for 24 to 48 hours—or a cardiac MRI to get a more detailed look [3][2].
- Continued Vigilance: Because heart changes have often been reported emerging in adolescence or adulthood, cardiac monitoring remains essential throughout the lifespan, even if the person feels perfectly fine [4][1].
Respiratory and Sleep Monitoring
As muscle weakness progresses, the muscles that help the lungs expand can become tired. This often shows up first during sleep, a condition called nocturnal hypoventilation [5].
- Pulmonary Function Tests (PFTs): Once a patient is old enough and able to follow directions, they may have regular breathing tests as a baseline [6]. A key test involves measuring breathing while sitting up and then while lying flat; a significant drop in strength when lying down is a clue that prompts a pulmonologist to evaluate if sleep support is needed [5].
- Sleep Studies (Polysomnography): If there are morning headaches, daytime sleepiness, or frequent nighttime waking, a sleep study can help a pulmonologist determine if noninvasive ventilation like a BiPAP machine is appropriate [5][7].
Neurological and Developmental Checkups
Because DPM3-CDG can involve the brain, regular neurological reviews are essential to track milestones and screen for seizures [8].
- Seizure Vigilance: Epilepsy in CDG can be subtle. The neurologist will ask about “staring spells” or unusual movements. If seizures are suspected, an EEG (a test of the brain’s electrical activity) will be ordered [9][10].
- Developmental Support: Periodic cognitive and physical assessments ensure that school or workplace accommodations and therapies (PT/OT) are adjusted as needs change [8][11].
The Emotional Reality of Monitoring
Living with an ultra-rare diagnosis means living with uncertainty. The “diagnostic odyssey” is often followed by a “monitoring odyssey,” which can take a significant psychological toll [12][13].
It is common for patients and families to experience anxiety or fatigue related to frequent medical appointments and the wait for test results [11]. Building a support network—including genetic counselors, social workers, and other rare-disease families—is not just an “extra” step; it is a vital part of managing the condition [14][13]. Remember that the disease trajectory is highly variable; a specific path cannot be predicted by the genetic code alone, and a coordinated team is your best tool for navigating the years ahead [8].
Common questions in this guide
How often should heart tests be repeated in DPM3-CDG?
What breathing and sleep checks may be needed for DPM3-CDG?
How can families watch for seizures or neurological changes?
Why does DPM3-CDG need lifelong monitoring?
What support can help with the stress of repeated monitoring?
What does developmental follow-up look like for someone with DPM3-CDG?
One line in your results can change your plan.
A significant drop in strength when lying down is a clue that prompts a pulmonologist to evaluate whether sleep support is needed. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on DPM3-CDG.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene.
Svahn J, Laforêt P, Vial C, et al.
Neuromuscular disorders : NMD 2019; (29(7)):497-502 doi:10.1016/j.nmd.2019.05.004.
PMID: 31266720 - 2
2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.
Groh WJ, Bhakta D, Tomaselli GF, et al.
Heart rhythm 2022; (19(10)):e61-e120 doi:10.1016/j.hrthm.2022.04.022.
PMID: 35500790 - 3
Reconsidering a silent variant: SGCA's role in atypical cardiomyopathy.
Horowitz-Cederboim S, Hoffman-Lipschuetz R, Durst R, et al.
European journal of human genetics : EJHG 2026; (34(4)):528-534 doi:10.1038/s41431-025-01981-z.
PMID: 41345255 - 4
Cardiomyopathy in limb girdle muscular dystrophy R9, FKRP related.
Libell EM, Richardson JA, Lutz KL, et al.
Muscle & nerve 2020; (62(5)):626-632 doi:10.1002/mus.27052.
PMID: 32914449 - 5
Comparison of sitting and supine forced vital capacity in collagen VI-related dystrophy and laminin α2-related dystrophy.
Meilleur KG, Linton MM, Fontana J, et al.
Pediatric pulmonology 2017; (52(4)):524-532 doi:10.1002/ppul.23622.
PMID: 28085238 - 6
Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study.
Bouman K, Groothuis JT, Doorduin J, et al.
BMC neurology 2021; (21(1)):313 doi:10.1186/s12883-021-02336-z.
PMID: 34384384 - 7
Early Onset of Sleep-Disordered Breathing in Two Children With SEPN1-Related Myopathies.
Viprey M, Trang H, Pomedio M, et al.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2017; (13(9)):1105-1108 doi:10.5664/jcsm.6734.
PMID: 28558865 - 8
A recurrent homozygous missense DPM3 variant leads to muscle and brain disease.
Nagy S, Lau T, Alavi S, et al.
Clinical genetics 2022; (102(6)):530-536 doi:10.1111/cge.14208.
PMID: 35932216 - 9
Congenital disorders of glycosylation and infantile epilepsy.
Lee HF, Chi CS
Epilepsy & behavior : E&B 2023; (142()):109214 doi:10.1016/j.yebeh.2023.109214.
PMID: 37086590 - 10
Abnormal protein glycosylation in epileptogenesis: evidence from experimental models and clinical insights.
Liu G, Liu S, Wang G, et al.
Reviews in the neurosciences 2026; (37(5)):505-517 doi:10.1515/revneuro-2026-0011.
PMID: 42242704 - 11
Patient-reported outcomes and quality of life in PMM2-CDG.
Ligezka AN, Mohamed A, Pascoal C, et al.
Molecular genetics and metabolism 2022; (136(2)):145-151 doi:10.1016/j.ymgme.2022.04.002.
PMID: 35491370 - 12
Mapping the diagnostic odyssey of congenital disorders of glycosylation (CDG): insights from the community.
Granjo P, Pascoal C, Gallego D, et al.
Orphanet journal of rare diseases 2024; (19(1)):407 doi:10.1186/s13023-024-03389-2.
PMID: 39482754 - 13
Resilience in patients and family caregivers living with congenital disorders of glycosylation (CDG): a quantitative study using the brief resilience coping scale (BRCS).
Poejo J, Gomes AI, Granjo P, Dos Reis Ferreira V
Orphanet journal of rare diseases 2024; (19(1)):98 doi:10.1186/s13023-024-03043-x.
PMID: 38439013 - 14
Genetic counseling for congenital disorders of glycosylation (CDG).
Weixel T, Wolfe L, Macnamara EF
Journal of genetic counseling 2024; (33(6)):1358-1364 doi:10.1002/jgc4.1856.
PMID: 38240170
This page explains long-term monitoring for DPM3-CDG for educational purposes only and is not medical advice. Testing and follow-up should be personalized with your care team.